- HOME
- Products & Services
- Oligonucleotide API CRDMO – Service Overview
-
Oligonucleotide API CRDMO
- Oligonucleotide API CRDMO – Service Overview
- Antisense Oligonucleotide (ASO) Design & Synthesis
- RUO Oligonucleotide Synthesis (in vitro / in vivo)
- Evaluation of Off-target Effects
- Cell-Based Assays & Screening
- Animal Experimentation & Non-Clinical Trial
- GMP Oligonucleotide APIs: Manufacturing & Quality Control
-
Custom DNA/RNA Synthesis
-
Next Generation Sequencing
- Next Generation Sequencing
-
Application Selection Guide
- Application Selection Guide
- Human Genome Sequencing
- Whole Genome Sequencing (Non-Human)
- Microbial genome sequencing
- Small scale sequencing (NGS Petit)
- GRAS-Di® Genotyping
- Repeat Motif Detection
- Library Prep for Challenging DNA Samples
- Gene Expression Analysis (Reference-Based)
- Isoform Sequencing (full-length mRNA-seq)
- De novo Transcriptome Sequencing
- Small RNA-Seq
- Microbial Community Analysis
- Shotgun Metagenomic Sequencing
- Metatranscriptome Sequencing
- ChIP-Seq
- CRISPR Screening
- Illumina Amplicon Sequencing
- PacBio Amplicon Sequencing
- Standard Pipeline Data Analysis
- Custom Data Analysis
- Gene Analysis from Pathological Specimens
- Sequencer Models and Sequencing Principles
- Sample Requirements
- How to Order
- Scientific Publications
-
Custom DNA Sequencing
-
Custom DNA Microarray
-
Protein Related Service
-
Laboratory Tools and Service
Oligonucleotide API CRDMO – Service Overview
Service Description
Hokkaido System Science Co., Ltd. (HSS) comprehensively supports the research and development of oligonucleotide therapeutics, covering sequence design, synthesis, cell-based assays, animal experimentation, and gene analysis.
In addition, through a joint collaboration with Mitsubishi Gas Chemical Company, Inc. (MGC), we have established a GMP-compliant oligonucleotide manufacturing platform, enabling seamless, end-to-end support from early-stage research through to oligonucleotide API manufacturing.
Press Release: Business Collaboration Agreement for exploring Entry into Nucleic Acid Drug CDMO Business (July 12, 2024)
Interview: “AXELPHEX™” Accelerating the Social Implementation of Nucleic Acid Therapeutics: The Future Envisioned by an Evolving CRDMO_in English (September 30, 2026 | Saisachi, a research information website operated by RIKAKEN HOLDINGS Co., Ltd.) [External site]
Features of HSS Custom Services
Contact & Consultation
If you have any questions or would like to request a quote,
please feel free to contact us using the form below.